Psychopharmacology
The CRH-1 receptor antagonist pexacerfont is currently under investigation for the treatment of generalized anxiety disorder in women. Another CRH-1 antagonist antalarmin has been researched in animal studies for the treatment of anxiety, depression and other conditions, but no human trials with this compound have been carried out.
Also, abnormally high levels of CRH have been found in the cerebrospinal fluid of people that have committed suicide.
Recent research has linked the activation of the CRH1 receptor with the euphoric feelings that accompany alcohol consumption. A CRH1 receptor antagonist developed by Pfizer, CP-154,526 is under investigation for the potential treatment of alcoholism.
Read more about this topic: Corticotropin-releasing Hormone